Sarepta wins new drug approval for patients with Duchenne muscular dystrophy, its third marketed treatment
The Food and Drug Administration on Thursday approved a new medicine from Sarepta Therapeutics that treats certain patients with Duchenne muscular dystrophy.
The new drug, called Amondys 45, is Sarepta’s third marketed treatment for the rare, inherited muscle-wasting disease. It will be used to treat the approximately 8% of patients with a confirmed mutation to the Duchenne gene that is amenable to exon 45 skipping.
